1 Mazzaferri EL, "Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma" 7 (7): 265-271, 1997
2 Randolph GW, "The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension" 22 (22): 1144-1152, 2012
3 Nixon IJ, "The impact of nodal status on outcome in older patients with papillary thyroid cancer" 156 (156): 137-146, 2014
4 Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer" 366 (366): 1663-1673, 2012
5 American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer" 19 (19): 1167-1214, 2009
6 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 (91): 926-932, 2006
7 Leboulleux S, "Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis" 90 (90): 5723-5729, 2005
8 Castagna MG, "Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients" 169 (169): 23-29, 2013
9 Furtado Mde S, "Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis" 59 (59): 285-291, 2015
10 de Meer SG, "Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer" 36 (36): 1262-1267, 2012
1 Mazzaferri EL, "Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma" 7 (7): 265-271, 1997
2 Randolph GW, "The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension" 22 (22): 1144-1152, 2012
3 Nixon IJ, "The impact of nodal status on outcome in older patients with papillary thyroid cancer" 156 (156): 137-146, 2014
4 Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer" 366 (366): 1663-1673, 2012
5 American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer" 19 (19): 1167-1214, 2009
6 Pacini F, "Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study" 91 (91): 926-932, 2006
7 Leboulleux S, "Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis" 90 (90): 5723-5729, 2005
8 Castagna MG, "Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients" 169 (169): 23-29, 2013
9 Furtado Mde S, "Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis" 59 (59): 285-291, 2015
10 de Meer SG, "Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer" 36 (36): 1262-1267, 2012
11 Schneider DF, "Lymph node ratio predicts recurrence in papillary thyroid cancer" 18 (18): 157-162, 2013
12 Sabra MM, "Higher administered activities of radioactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases" 24 (24): 1088-1095, 2014
13 Jeon MJ, "Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma" 81 (81): 593-599, 2014
14 하승균, "Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer" 대한의학회 30 (30): 876-881, 2015
15 Smith VA, "Cervical lymph node metastasis and papillary thyroid carcinoma: does the compartment involved affect survival? Experience from the SEER database" 106 (106): 357-362, 2012
16 Sohn SY, "Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer" 23 (23): 741-747, 2013
17 Beierwaltes WH, "An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: experience at University of Michigan" 25 (25): 1287-1293, 1984
18 Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer" 366 (366): 1674-1685, 2012
19 The American Joint Committee on Cancer, "AJCC cancer staging manual" Springer 87-96, 2010
20 Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer" 26 (26): 1-133, 2016